XML 42 R61.htm IDEA: XBRL DOCUMENT v2.4.1.9
Debt - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
0 Months Ended 12 Months Ended 1 Months Ended
Jun. 30, 2014
Tranche
Dec. 31, 2014
Apr. 30, 2013
May 31, 2014
Loan and Security Agreement        
Line of Credit Facility [Line Items]        
Maximum borrowing limit $ 30.0us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Term of agreement 5 years      
Number of loan tranches 3cers_NumberOfEqualTranches
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Interest rate, description   Term Loan A bears an interest rate of 6.95%. Term Loan B and Term Loan C will bear an interest rate calculated at the greater of 6.95% or 6.72% plus the three month U.S. LIBOR rate in effect three business days prior to the applicable Term Loan funding date.    
Maturity period   Jun. 01, 2019    
Principal and interest payments 42 months      
Final payment term percent 7.00%cers_LineOfCreditFacilityFinalPaymentPercentageOfPrincipalDrawnAtMaturity
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Terms of required periodic payments of interest and principal   The Company is required to make interest only payments through December 2015 followed by forty-two months of equal principal and interest payments thereafter; however, if the Revenue Event is achieved no later than November 30, 2015, then the interest-only period may be extended through December 31, 2016, and the amortization period will be reduced to thirty months. The Company is also required to make a final payment equal to 7% of the principal amounts of the Term Loans drawn payable on the earlier to occur of maturity or prepayment.    
Commitment fee 0.2us-gaap_DebtInstrumentFeeAmount
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Lender legal fees 0.1us-gaap_LegalFees
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Loan and Security Agreement | Securities Pledged as Collateral        
Line of Credit Facility [Line Items]        
Percentage of investments made in subsidiary 35.00%cers_PercentageOfInvestmentsMadeInSubsidiary
/ us-gaap_FinancialInstrumentAxis
= us-gaap_SecuritiesPledgedAsCollateralMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Amended Credit Agreement        
Line of Credit Facility [Line Items]        
Maturity period   Jun. 30, 2014    
Amended Credit Agreement | Revolving line of credit ("RLOC")        
Line of Credit Facility [Line Items]        
Maximum borrowing limit   7.0us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_LongtermDebtTypeAxis
= cers_AmendedCreditAgreementMember
   
Loan and security agreement       3.4us-gaap_LineOfCredit
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_LongtermDebtTypeAxis
= cers_AmendedCreditAgreementMember
Amended Credit Agreement | Term Loan        
Line of Credit Facility [Line Items]        
Maximum borrowing limit   5.0us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
/ us-gaap_CreditFacilityAxis
= cers_TermLoanMember
/ us-gaap_LongtermDebtTypeAxis
= cers_AmendedCreditAgreementMember
   
Loan and security agreement     5.0us-gaap_LineOfCredit
/ us-gaap_CreditFacilityAxis
= cers_TermLoanMember
/ us-gaap_LongtermDebtTypeAxis
= cers_AmendedCreditAgreementMember
 
Final payment fee for early repayment of credit facility     0.05us-gaap_PaymentsOfDebtExtinguishmentCosts
/ us-gaap_CreditFacilityAxis
= cers_TermLoanMember
/ us-gaap_LongtermDebtTypeAxis
= cers_AmendedCreditAgreementMember
 
Repayment of credit facility     4.2us-gaap_RepaymentsOfLinesOfCredit
/ us-gaap_CreditFacilityAxis
= cers_TermLoanMember
/ us-gaap_LongtermDebtTypeAxis
= cers_AmendedCreditAgreementMember
 
First Tranche (Term Loan A) | Loan and Security Agreement        
Line of Credit Facility [Line Items]        
Loan and security agreement 10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_FirstTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Interest rate 6.95%us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd
/ us-gaap_DebtInstrumentAxis
= cers_FirstTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Second Tranche (Term Loan B) | Loan and Security Agreement        
Line of Credit Facility [Line Items]        
Loan and security agreement 10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_SecondTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Borrowing conditions   The second tranche of $10.0 million ("Term Loan B") was contingent upon the approval, by the U.S. Food and Drug Administration ("FDA") of the Company's premarket approval application for either the plasma or platelet system (the "PMA Approval"), which occurred in December 2014. The availability of Term Loan B expires on June 15, 2015.    
Third Tranche (Term Loan C) | Loan and Security Agreement        
Line of Credit Facility [Line Items]        
Loan and security agreement $ 10.0us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= cers_ThirdTrancheMember
/ us-gaap_LongtermDebtTypeAxis
= cers_LoanAndSecurityAgreementMember
     
Borrowing conditions   The third tranche of $10.0 million ("Term Loan C") will be available from July 1, 2015 through December 31, 2015, contingent upon the Company achieving trailing six months' revenue at a specified threshold (the "Revenue Event").